Genomic profiling reveals heterogeneous populations of ductal carcinoma in situ of the breast

Commun Biol. 2021 Apr 1;4(1):438. doi: 10.1038/s42003-021-01959-9.

Abstract

In a substantial number of patients, ductal carcinoma in situ (DCIS) of the breast will never progress to invasive ductal carcinoma, and these patients are often overtreated under the current clinical criteria. Although various candidate markers are available, relevant markers for delineating risk categories have not yet been established. In this study, we analyzed the clinical characteristics of 431 patients with DCIS and performed whole-exome sequencing analysis in a 21-patient discovery cohort and targeted deep sequencing analysis in a 72-patient validation cohort. We determined that age <45 years, HER2 amplification, and GATA3 mutation are possible indicators of relapse. PIK3CA mutation negativity and PgR negativity were also suggested to be risk factors. Spatial transcriptome analysis further revealed that GATA3 dysfunction upregulates epithelial-to-mesenchymal transition and angiogenesis, followed by PgR downregulation. These results reveal the existence of heterogeneous cell populations in DCIS and provide predictive markers for classifying DCIS and optimizing treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Breast Neoplasms / genetics*
  • Carcinoma, Intraductal, Noninfiltrating / genetics*
  • Female
  • GATA3 Transcription Factor / genetics
  • GATA3 Transcription Factor / metabolism
  • Gene Amplification*
  • Gene Expression Profiling
  • Humans
  • Middle Aged
  • Mutation*
  • Receptor, ErbB-2 / genetics
  • Receptor, ErbB-2 / metabolism
  • Young Adult

Substances

  • GATA3 Transcription Factor
  • GATA3 protein, human
  • ERBB2 protein, human
  • Receptor, ErbB-2